CCF642|CCF-642|PD1 inhibitor

CCF642|CCF-642|PD1 inhibitor

CCF642 is a novel protein disulfide isomerases (PDI) inhibitor.

Product Name: CCF642|Cat No. DC9757|CAS: 346640-08-2|Other names:CCF 642,CCF-642|MW: 377.98|Molecule Formular: C15H10N2O4S3|Purity>98%

CCF642, a bone marrow-sparing compound, exhibited a submicromolar IC50 in 10 of 10 multiple myeloma cell lines. An active biotinylated analog of CCF642 defined binding to the PDI isoenzymes A1, A3, and A4 in MM cells. In vitro, CCF642 inhibited PDI reductase activity about 100-fold more potently than the structurally distinct established inhibitors PACMA 31 and LOC14. Computational modeling suggested a novel covalent binding mode in active-site CGHCK motifs. Remarkably, without any further chemistry optimization, CCF642 displayed potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolonged the lifespan of C57BL/KaLwRij mice engrafted with 5TGM1-luc myeloma, an effect comparable to the first-line multiple myeloma therapeutic bortezomib. Consistent with PDI inhibition, CCF642 caused acute ER stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release.

For research only, not for human use.